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IL-1  is the term used to describe a  group of factors, primarily macrophage- 
derived, that exhibit a  multitude of specific in vitro and in vivo effects. These 
effects  include  stimulation  of murine  thymocyte proliferation  in  vitro,  IL-2 
production, fever, fibroblast proliferation, enzyme and prostaglandin production 
by chondrocytes and synoviocytes, acute-phase protein production  by hepato- 
cytes,  bone  resorption,  fluctuations  in  circulating  levels  of  metal  ions,  and 
chemotactic and chemokinetic effects on leukocytes (reviewed in reference 1). It 
has been previously reported that IL-1 activity is primarily associated with several 
charged proteins having isoelectric points (pI) of 6.8, 5.4, and 5.2 (2-5). Partially 
purified preparations of the neutral (pI  6.8) and anionic forms (pI  5.4/5.2)  of 
IL-1 have been compared in a number of biological assay systems, with the result 
that all appeared to exhibit an identical spectrum of activities (6). This led to the 
conclusion  that  the  various  charged  species  of IL-1  must  be  closely related, 
perhaps differently processed, products of the same gene (6). 
Recently, several groups have cloned IL-1  cDNAs of murine (7) and human 
origin (8, 9). However, when the amino acid sequence deduced from the murine 
IL-1 cDNA (7) was compared with that deduced from the first reported cDNA 
for human IL-I  (8),  only ~30%  homology was observed (9,  10).  Since murine 
IL-1 is an anionic molecule (1 1) and the predominant human form is neutral, it 
seemed possible  that a  similar lack of homology might also exist between the 
anionic and neutral human IL-1 species. The subsequent report of an additional 
cDNA  for  human  IL-1  (IL-l-a,  reference 9)  supported  this  hypothesis.  The 
deduced amino acid sequence for the IL-I-~ cDNA displayed only 30% homology 
with the amino acid sequence deduced from the first reported human cDNA 
(since  designated  IL-1-/3),  but  60%  homology (9)  with  the  murine sequence, 
suggesting that it represented the human equivalent of routine IL-1, presumably 
an anionic form. 
These findings indicate that there are at least two human genes coding for 
molecules possessing IL-1 activity and that the IL-I-~ cDNA is likely to encode 
one or more of the anionic species of human IL-1. However, no direct evidence 
relating the IL-l-o~ cDNA, which was cloned using hybrid selection techniques 
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and  bioassay,  to  the  native  charged  species  of  IL-1  is  available.  The  pI  6.8 
molecule has been  purified  to homogeneity by us and  others  (10,  12-14),  and 
N-terminal  and  internal  amino  acid  sequence  analysis  proved  that  the  IL-I-~3 
cDNA  did  in  fact  encode  for  the  precursor  of  IL-1/6.8  (10).  However,  the 
anionic  forms  have  not  previously  been  purified  in  any  amount  suitable  for 
characterization and thus the relationship between these proteins and the cloned 
cDNAs remains unclear. 
We here report the purification to homogeneity of two anionic forms of human 
IL-1 having pIs of 5.2 (IL-1/5.2) and 5.4 (IL-1/5.4). Both IL-1/5.2 and IL-1/5.4 
are  indistinguishable  from  IL-1/6.8  in  terms  of  their  molecular  weights,  as 
determined  by  SDS  PAGE  and  specific  bioactivities  in  the  mouse  thymocyte 
proliferation assay.  Nevertheless, four antisera directed against  IL-1/6.8 do not 
crossreact with  either anionic protein.  Moreover, reverse-phase HPLC of cyan- 
ogen  bromide (CNBr) J peptides of IL-1/5.4  reveal  it to be structurally  distinct 
from  IL-1/6.8.  Amino  acid  sequence  analyses  of  intact  IL-1/5.2  and  CNBr 
peptides  of IL-1/5.4  show  complete  homology  with  the  amino  acid  sequence 
deduced from the IL-l-ex cDNA. 
Materials and  Methods 
Preparation  of IL-l-containing  Supernatants.  tL-l-containing supernatants  were  pre- 
pared as  previously described  (14).  Briefly,  human  PBMC  were  separated  by density 
gradient centrifugation (LSM, Bionetics Laboratory Products, Charleston, SC). Cells were 
cultured in serum-free RPMI (Gibco Laboratories, Grand Island, NY) at a density of 3 × 
109/150  cln 2 in  400  ml  of medium  for 4  d  in  the  presence of PHA (5  #g/ml;  Sigma 
Chemical Co., St.  Louis, MO) and LPS (1 #g/ml; Escherichia coli 055:B5, Sigma Chemical 
Co.).  Supernatants  were  concentrated  (300  x)  using  a  Pellicon  cassette  ultrafiltratio'n 
apparatus  (tool  wt  >10,000),  as  previously  described  (14),  then  dialyzed  against  the 
running buffer for the first ion exchange column. 
Purification of Two Anionic Species oflL-1.  This purification takes advantage of the fact 
that the anionic forms remain tightly bound to the HPLC-DEAE column (Bio-Gel TSK- 
DEAE-5-PW [21.5  x  150 mm]; Bio-Rad Laboratories, Richmond, CA) after the elution 
of IL-1/6.8, as previously described (10).  Briefly, 4  ml of dialyzed, concentrated super- 
natant  was loaded onto the  DEAE-HPLC column equilibrated  in  20  mM  Tris/Acetate 
(pH 8.3).  1L-1/6.8 was then eluted from the column with a descending pH gradient (pH 
8.3-6.8) at a flow rate of 4 ml/min at room temperature (10).  The column was washed 
extensively with  20  mM Tris/Acetate (pH 6.8) and the anionic forms were then batch- 
eluted with the same buffer containing 0.3 M sodium acetate. This resulted in the elution 
of all the remaining IL-1 activity. The column was then washed with  1 M sodium acetate 
to remove the remaining proteins. 
Five of the 0.3  M acetate elutions were pooled, concentrated in a stirred cell  using a 
YM 10 u/n-afiltration membrane (Amicon Corp., Danvers, MA), and subsequently dialyzed 
against 20 mM Tris/Acetate (pH 8.3).  This material was then rechromatographed on the 
HPLC-DEAE column. The conditions employed were the following: (a) the sample was 
applied in  20 mM Tris/Acetate (pH 8.3) to ensure complete binding and washed for 30 
rain at 4  ml/min with this buffer; (b) the column was then washed for an additional  30 
rain with  20 mM Tris/Acetate (pH 6.8); (c) the anionic forms of IL-1  were then eluted 
wilh a gradient of 0-300 mM sodium acetate in 20 mM Tris (pH 6.8) buffer at a rate of 
3 mM/min. The absorbance of the column effluent was monitored at 280  nm and 4 ml 
fractions were collected. Both the batch eluted material and the gradient eluted fractions 
were stored at 4°C  in  the presence of 10 ug/ml aprotinin  (Sigma Chemical Co.),  1 taM 
t Abbreviations used in this paper:  CNBr, cyanogen bromide;  PTH, phenylthiohydantoin;  TFA, 
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PMSF (Sigma Chemical Co.), and  0.025  M  EDTA.  IL-1 activity reproducibly eluted  as 
two major peaks, with minor peaks of activity occasionally observed. The active fractions 
from each of the two major peaks were pooled and concentrated on YM10 membranes 
to a volume of 1 ml before fractionation by preparative HPLC size-exclusion chromatog- 
raphy (TSK 2000SW [21.5 mm X 60 cm]; Bio-Rad Laboratories).  The column was run 
in  100 mM sodium phosphate (pH 6.8),  20% ethylene glycol, and 0.02% azide at a flow 
rate of 2  ml/min.  2  ml  fractions were collected and assayed.  The active fractions were 
then  chromatographed on a  Vydac C4 reverse-phase  HPLC column (4.6  mm  X  5  cm; 
Rainin) equilibrated  in 0.1% trifluoroacetic acid (TFA) in water. The colunm was eluted 
with a gradient (0-40%) ofacetonitrile containing 0.1% TFA. The gradient was developed 
rapidly (4 rain) to 36% acetonitrile,  followed by a  0.25%/rain  gradient at a  flow rate of 
0.5 ml/min.  The absorbance of the column effluent was monitored at 210 nm and peaks 
of interest  were manually peak-collected using a  Frac-100 fraction collector (Pharmacia 
Fine Chemicals, Piscataway, N  J). The peaks associated with IL-1 activity were rechroma- 
tographed by reverse-phase  HPLC, using the same conditions as above. The concentra- 
tions of the  purified  proteins  were calculated  by integration  of the  absorbance  profile 
obtained at 210 nm using the Nelson Analytical data acquisition system, Model 4416, run 
on a Hewlett Packard Co. (Palo Alto, CA) 9816 computer. Known amounts of ribonuclease 
were used to calibrate the integration function of the data aquisition system. 
Isoelectric Focusing.  Isoelectric focusing of IL-1 was performed as previously described 
(14).  The  pH  gradients  were  standardized  with  proteins  of known  pI,  as  previously 
described (14).  Gels were cut into 2  mm slices  and eluted  into 0.5  ml  RPMI/10%  FCS 
overnight  at  4°C.  Samples  were  assayed  for  IL-1  activity  in  the  mouse  tbymocyte 
proliferation assay at dilutions of 1:5 and  1:20. 
Analytical SDS-PAGE.  Samples (50-150 ng) were diluted into Laemmli sample buffer 
containing  1 mM dithiothreitol  and boiled for 5  min before SDS-PAGE in vertical slab 
gels containing  15%  acrylamide.  Gels  were stained  with  silver,  as previously described 
(15).  Standard  proteins  consisting  of phosphorylase  b  (tool  wt  94,000),  BSA  (mol  wt 
67,000)  OVA  (tool  wt  43,000),  carbonic anhydrase  (tool  wt  30,000),  soybean  trypsin 
inhibitor (mol wt 20,100), and alpha-lactalbumin  (mol wt  14,400) were run on the same 
gel slab and  molecular weights of the  IL-1  species were calculated by linear  regression 
analysis of the molecular weights of the standards. 
Thymocyte Proliferation (Lymphocyte Activating Factor [LAF]) Assay.  IL-1  activity  was 
monitored  using  the  mouse  thymocyte  comitogenic  proliferation  assay  performed  as 
previously described (14)  using 6-8-wk-old C3H/HeJ  male mice.  Half-maximal  units of 
bioactivity were calculated as previously described (10). 
Preparation and  Assay of Anti-lL-l/6.8  Antisera.  Antisera  were  raised  in  rabbits  to 
KLH-conjugated synthetic peptides, as previously described (I 6). Antiserum to intact IL- 
1/6.8  was raised  in  rabbits  by immunization  with  3  ug of pure  IL-1/6.8  (10)  in saline 
injected into the popliteal lymph nodes (day 0), followed by a subcutaneous injection with 
3 #g in CFA (day 21). Rabbits were boosted three times by intramuscular injection of 3- 
10 ugs  IL-1/6.8  in  IFA on  days 43,  57,  82,  and  152  and  they were bled  on day  163. 
Antibody binding was assayed using ELISA or Western analysis, as previously described 
(16). 
CNBr Cleavage oflL-1/5.4.  Reverse-phase-purified  IL-1/6.8  and  IL-1/5.4 (4  ug  in 
100 #l) were brought to 50% TFA (vol/vol), and 1 mg of CNBr in 10 ul water was added. 
After incubation for 24 h in the dark at room temperature, the entire sample was diluted 
1:5 in  water and injected  directly onto an  Aquapore Bu-300 reverse-phase column (2.1 
mm×  3 cm; Brownlee Labs, Santa Clara, CA) equilibrated in 0.1% TFA/90% water/10% 
acetonitrile.  Peptides were eluted fi'om the column with a 2%/rain gradient of acetonitrile 
at a flow rate of 0.2 ml/min.  Peaks were collected into polypropylene tubes and stored at 
4°C. 
Amino Acid Sequence Analysis.  Intact  IL-1/5.2  or  IL-1/5.4 peptides  were applied  by 
repeated application to polybrene-coated filters and sequenced  using an automated gas- 
phase  sequencer  employing Edman  chemistry  (model  470A;  Applied  Biosystems,  Inc., 
Foster  City,  CA).  The  ATZ  amino  acids  were  treated  in  the  conversion  flask  with 240  PURIFICATION  OF  TWO  ANIONIC  SPECIES  OF  INTERLEUK1N  1 
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FIGURE  1.  DEAE/HPLC chromatography of anionic species of human IL-1. 0.3  M  sodium 
acetate-eluted material from five column runs was reapplied and eluted with a sodium acetate 
gradient at  a  rate  of 3  mM/min,  as described  in  Materials  and  Methods.  Absorbance was 
monitored at  280  nm and fractions were assayed at  a  dilution of 1:8,000  in the thymocyte 
proliferation (LAF) assay. The fractions under the horizontal bars (IL-1/I and IL-1/II) were 
pooled for further purification steps. 
methanolic-HCl  to form the methyl esters of the phenylthiohydantoin (PTH) derivatives 
of glutamic  acid and aspartic  acid.  The  PTH amino acids were identified  by isocratic 
separation  on a Zorbax Bioseries PTH/HPLC column (Dupont Co., Wilmington,  DE) as 
per the manufacturer's instructions. 
Results 
Purification oflL-1/5.2 and IL-1/5.4.  As previously reported (10), IL-1/6.8 is 
purified on a  DEAE/HPLC column  using a  pH gradient  elution  protocol (pH 
8.3-6.8). After this step, a significant amount of IL-1 activity is still firmly bound 
to the column.  In preliminary experiments, all the remaining activity was found 
to elute in 0.3 M sodium acetate (pH 6.8). The amount of activity recovered at 
this step was ~20% of the total activity of the starting  material.  To accumulate 
enough material for further purification,  five batches eluted with 0.3 M sodium 
acetate were then pooled and concentrated. 
Fig. 1 shows the absorbance and activity profiles of this material when reapplied 
to the DEAE/HPLC column and eluted with a shallow gradient of sodium acetate 
(see Materials and  Methods). The  two areas of thymocyte proliferation  activity 
indicated by the horizontal bars (designated I E-1/I and I L-1/I I) were separately 
pooled and concentrated in preparation for size-exclusion chromatography. Both 
of these anionic species of IL-1  eluted from a preparative  TSK2000 column in 
nearly identical elution volumes (126-130 ml), as measured by thymocyte stim- 
ulating activity (data not shown). This elution volume represented a tool mass of 
17-18 kD when compared with standards of known mol mass, and was identical 
to that seen with IL-1/6.8.  Fig. 2 (A and C) shows the absorbance profiles when 
the  two  anionic  species  eluted  from  the  TSK2000  column  were  separately 
chromatographed  on  a  Vydac  C4  reverse-phase  column  equilibrated  in  0.1% 
TFA in water. Fig. 2 (B and D) shows the corresponding activity profiles obtained 
when the peak-collected fractions were tested for IL-I activity. Both anionic IL- CAMERON  ET  AL.  241 
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FIGURE 2.  Reverse-phase  HPLC  of anionic species of human  IL-1.  Active fractions from 
ion-exchange  HPLC  (IL-1/I  and  IL-1/II;  see  Fig.  1)  were  each  further  purified  by  size- 
exclusion HPLC (data not shown). The active fractions from these runs were chromatographed 
on a Vydac C4 reverse-phase column as described in Materials and Methods (A and B, IL-I/I; 
C and D, IL-1/ll). Absorbance was monitored at 210 nm (A and C) and activity (U/fraction) 
was measured in the murine thymocyte assay (B and D). 
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FIGURE 3.  Rechromatography  of anionic species of human IL-1  on reverse-phase HPLC. 
The peaks corresponding with the active fractions from the Vydac C4 column (Fig.  2) were 
rechromatographed using the same protocol as in Fig. 2. (A) IL-1/I, (B) IL-1/II. The stippled 
areas represent those portions of the peaks that were collected for subsequent analysis. 
1  s had similar, but not identical, retention times of-20  min, which represented 
an  acetonitrile  concentration  of ~39%.  In  contrast,  IL-1/6.8  elutes  in  ~33% 
acetonitrile under identical gradient conditions (data not shown). Injection of a 
mixture  of the  pure  anionic  species yielded a  double peak  (data  not  shown), 
indicating that the slight difference in retention time observed when the species 
were chromatographed  separately was not due to run  variation.  Rechromatog- 
raphy of the peaks in Fig. 2 corresponding with IL-1 activity is shown in Fig. 3. 
>95% of the integrated area was found under single, sharp,  symmetrical peaks 
in each case. The stippled areas represent those portions of the peaks that were 
collected for subsequent analyses. SDS-PAGE of these materials is shown in Fig. 
4.  Both preparations  gave single,  silver-staining  bands (lanes  3  and  4) with  an 242  PURIFICATION  OF  TWO  ANIONIC  SPECIES  OF  INTEREEUKIN  l 
FIGURE 4.  Silver-stained SDS-PAGE of anionic and  neutral  human  IL-I  species.  Materials 
represented by the stippled areas in Fig. 3 were subjected to SDS-PAGE along with IL-1/6.8, 
purified as previously described (10),  and standard  proteins of known molecular weights (see 
Materials and Methods). (Lanes 1 and 5) standard  proteins, (lane 2) IL-1/6.8, (lane 3) IL-I/1 
(Fig. 3A), (lane 4) IL-1/ll (Fig. 3B).  Molecular weights shown are ×10 -3. 
apparent  tool  wt of" 17,500.  This  tool  wt  is  indistinguishable  from  that  of IL- 
1/6.8  (lane 2).  Two high  mol wt bands are also seen. Their presence in all  the 
loaded lanes, including those containing the tool wt markers,  indicates that they 
represent contaminants  in the sample buffer. A doublet of this mobility is often 
seen  oil  silver-stained  gels  (17).  Finally,  the  pure  proteins  were  subjected  to 
isoelectric  focusing  in  separate  lanes  to  determine  their  respective  isoelectric 
points. Peaks of I L- 1 activity corresponding with pIs of 5.2 and 5.4 were observed 
(Fig.  5B).  These  peaks  were  found  to coincide exactly with a  double  peak  of 
activity observed when  batch-eluted  material  from  the first  DEAL column  was 
subjected to isoelectric focusing in a third  lane (Fig. 5A). 
Tile amount of activity represented by the pure IL-1/5.4 and IL-1/5.2 accounts 
for -6%  of the activity found in  the  material  batch-eluted  with  0.3  M  sodium 
acetate.  The  total  amount  of  IL-1/5.2  and  IL-1/5.4  recovered  from  crude, 
unconcentrated supernatant  was ~0.8 p.g/liter. 
Activity of Purified IL-I Species in the Mouse Thymocyte Assay.  Pure preparations 
of IL-1/6.8,  II.-1/5.4,  and  IL-1/5.2  were assayed for their  ability to stimulate 
the proliferation of mouse thymocytes in the presence of PHA. Fig. 6 illustrates 
a  representative  experiment  in  which  all  three  IL-1  species  were  found  to 
stimulate thymocyte proliferation in a dose-responsive manner. Specific activities, 
as  defined  by  that  amount  of  IL-1  which  gives  half-maximal  stimulation  of 
thymocyte proliferation,  were indistinguishable among all three charged species. 
The  concentrations  necessary  for  half-maximal  stimulation,  calculated  from 
linear regression of the data shown, averaged 430 pg/ml (range, 425-438 pg/ml), 
or ~2 x  10  -~ M. This represents a specific activity in the thymocyte proliferation 
assay (0.2  ml  volume) of 1.2  ×  l0 7 half-maximal  U/mg.  Identical  results  were 
obtained with three other purified preparations of IL-1/5.2 and IL-1/5.4. 
Antigenic Differences  between IL-1/6.8 and the Anionic IL-1 Species.  Antibodies 
directed  against  either  intact  IL-1/6.8  or synthetic  peptides  of IL-1/6.8  were CAMERON  ET  AL.  243 
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FIGURE  5.  Isoelectric focusing of anionic human  IL-I  species. (A)  15  #1  of 0.3  M  sodium 
acetate-eluted material containing both anionic forms of IL-1. (B) IL-I/I (O) and IL-1/II (A). 
100  ng of the materials shown in  Fig.  3,  A  and B  were subjected to isoelectric focusing in 
separate lanes. Gels were cut  into 2-mm slices and eluted into 0.5  ml  RPMI/FCS.  Samples 
were assayed in the mouse thymocyte assay at a  1:5 dilution (A) or a  1:20 dilution (B).  The 
pH  gradient was determined by focusing  1 !  standard proteins of known pI  in an adjacent 
lane. 
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FICVRE  6.  Titration of 1L-1/6.8,  IL-1/5.4, and IL-1/5.2 in the mouse thymocyte prolifera- 
tion assay. Materials shown in Fig. 3, A and B, as well as pure IL-1/6.8, were assayed for their 
ability to stimulate the proliferation of murine thymocytes in the presence of PHA.  Protein 
concentration was determined by measuring absorbance at 210 nm in comparison with known 
amounts of RNase as described in Materials and Methods. 244  PURIFICATION  OF  TWO  ANIONIC  SPECIES  OF  INTERLEUKIN  1 
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FIGURE  7.  ELISA, testing ability of four (A-D)  anti-lL-1/6.8 antisera to crossreact with IL- 
1/5.2 and IL-1/5.4. 10 ng of each species were allowed to bind to the wells before addition of 
the diluted antiserum and other reagents (see Materials and  Methods). (A) anti-N-terminal 
peptide; (B) anti-internal peptide; (C) anti-C-terminal peptide; (D) antML-I/6.8. 
tested for their  ability to bind  to equal  amounts  of immobilized  IL-1/6.8,  IL- 
1/5.4, and  IL-1/5.2 in an ELISA.  As shown in  Fig.  7,  no cross-reactivity could 
be shown with any of the four antisera tested. All four antisera were also strongly 
reactive  with  IL-1/6.8  on  Western  analysis,  but  were  completely  nonreactive 
with equal amounts of IL-5.2 and ]L-5.4 (data not shown). These results suggest 
that little or no antigenic similarity exists between the neutral and anionic species 
of human  IL-1. 
Amino Acid Sequence Analysis of IL-1/5.4 and IL-I/5.2.  Attempts at direct N- 
terminal sequence analysis of IL-1/5.4 were unsuccessful. Therefore, preparation 
of CNBr  peptides  of IL-1/5.4  was  performed  as  described  in  Materials  and 
Methods.  As can be seen in  Fig.  8A,  three prominant  peptides were separated 
by reverse-phase HPLC. The ascending baseline is characteristic of the gradient 
protocol  used,  and  the  large  peak  at  22  min  was  also  present  in  the  control 
reaction  mixture  without  protein.  The  reverse-phase  chromatograph  of  the 
CNBr peptides of IL-1/5.4  (Fig.  8A) was markedly different from that  of IL- 
l/6.8 CNBr peptides generated and chromatographed under identical conditions 
(Fig. 8B). The indicated peaks in Fig. 8A (I, II, and III) were sequenced and the CAMERON  ET  AL.  245 
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FIGURE 8.  Reverse-phase HPLC of CNBr peptides of IL-1/5.4 (A) and IL-1/6.8 (B).  Both 
IL-1 species were treated with CNBr as described in Materials and Methods. I, II, and III in 
A indicate the peptides that were subsequently sequenced and shown in Fig. 9. In each panel, 
the arrow indicates that time at which the corresponding intact protein eluted. Data acquisition 
during the run shown in B was stopped at 26 min. 
A  IL-1/5.4 
Peptide I: 
(Gly)  Ala  Tyr 
lie  Leu  Arg 
Peptide I1: 
Pro  Glu  Ite 
Leu  Phe  Phe 
Peptide lit: 
Arg  lie  lie 
Gin  (Set)  lie 
Ala  Leu  ? 
?  Ser  Ser  ?  Asp  Asp  Ata  ?  lie  Thr  Val 
lie  ? 
Pro  ?  (Thr)  lie  ?  (Gly)  ?  Glu  ?  Ash  Leu 
?  Glu  ? 
?  Tyr  Glu  Phe  lie  Leu  Ash  Asp  Ala  Leu  Asn 
lie  (Arg)  Ala  Asn  Asp  Gin  Tyr  Leu  (Thr)  Ala  Ala 
Asn  Leu  (Asp)  Glu  Ala  ?  ?  (Phe)  ? 
B  IL-1/5.2 
Amino Terminus'. 
Leu  Ser  Asn  Val  (Lys)  Tyr  Asn  Phe  Met  Arg  lie  lie  ?  Tyr 
Glu  Phe  lie  Leu  Ash  Asp  Ala  Leu  Asn  Gin  (Ser)  lie  lie  Arg 
(Ala)  ~  Asp  Gin  Tyr  Leu  ?  Ala  Ala  Ala  Leu  His  ? 
FIGURE 9.  (A) Amino acid sequences of CNBr peptides of human IL-1/5.4. Amino acids in 
parentheses indicate tentative identifications. I,  II, and III refer to the peaks in Fig.  8.  (B) 
Amino terminal sequence of IL-1/5.2. Complete homology was observed between peptide III 
of I L-1/5.4 and the amino terminal sequence of I L-1/5.2, except for the underlined residues. 
results are  shown  in  Fig.  9A.  Direct N-terminal  sequence analysis of IL-1/5.2 
was then performed. The results are shown in Fig. 9B. The amino acids shown 
in Fig. 9 A and B correspond exactly with the amino acid sequence deduced from 246  PURIFICATION  OF  TWO  ANIONIC  SPECIES  OF  INTERLEUKIN  l 
Met  Ala  Lys  Val  Pro  Asp  Met  Phe  Glu 
Asp  Ser  Ser  Ser  lie  Asp  His  Leu  Ser 
Gly  Pro  Leu  His  Glu  Gly  Cys  Met  Asp 
Lys  Thr  Ser  Lys  Leu  Thr  Phe  Lys  Glu 
Leu  Lys  Lys  Arg  Arg  Leu  Ser  Leu  Ser 
Ala  Asn  Asp  Ser  Glu  Glu  Glu  lie  lie 
Ash  Val  kys  Tyr  Asn  Phe  Met  Arg  lie 
Asn  Gin  Set  lie  lie  Arg  Ala  Ash  Asp 
Asp  Glu  Ala  Val  Lys  Phe  Asp  Met  Gly 
Thr  Val  lie  Leu  Arg  lie  Ser  Lys  Thr 
Pro  Val  Leu  Leu  Lys  Glu  Met  Pro  Glu 
Leu  Leu  Phe  Phe  Trp  Glu  Thr  His  Gly 
Asn  Leu  Phe  lie  Ala  Thr  Lys  Gin  Asp 
lie  Thr  Asp  Phe  Gin  lie  Leu  Glu  Asn 
10  20 
Asp  Leu  Lys  Asn  Cys  Tyr  Ser  Glu  Asn  Glu  Glu 
30  40 
Leu  Asn  Gin  Lys  Ser  Phe  Tyr  His  Val  Ser  Tyr 
50  60 
Gin  Ser  Val  Ser  Leu  Ser  lie  Ser  Glu  Thr  Ser 
70  80 
Ser  Met  Val  Vat  Vat  Ata  Yhr  Asn  G~y  Lys  Val 
90  100 
Gin  Ser  lie  Thr  Asp  Asp  Asp  Leu  Glu  Ala  lie 
110  120 
Lys  Pro  Arg  Ser  Ala  Pro  Phe  Ser  Phe  Leu  Set 
130  140 
lie  Lys  l~/r  Glu  Phe  Ile  Leu  Asn  Asp  Ala  Leu 
150  160 
Gin  "~jr Leu  Thr  Ala  Ala  Ala  Leu  His  Ash  Leu 
170  180 
Ala  Tyr  Lys  Ser  Ser  Lys  Asp  Asp  Ala  Lys  lie 
190  200 
Gin  Leu  Tyr  Val  Thr  Ala  Gin  Asp  Glu  Asp  Gin 
210  220 
lie  Pro  Lys  Thr  lie  Thr  Gly  Ser  Glu  Thr  Ash 
230  240 
Thr  Lys  Asn  Thr  Phe  Thr  Ser  Val  Ala  His  Pro 
250  260 
Tyr  Trp  Val  Cys  Leu  Aia  Gty  GIy  Pro  Pro  Ser 
270 
Gin  Ala 
FIGURE  10.  Comparison of amino acid sequences of IL-1/5.2 and 1L-1/5.4 with the amino 
acid sequence deduced from cDNA IL- 1-c~ (9). Amino acids in bold type indicate those residues 
confirmed by amino acid sequence analysis of CNBr peptides of native IL-1/5.4 (Fig. 9A) and 
N-terminal sequence analysis of IL-1/5.2 (Fig. 9B). 
the  cDNA  reported  by  March  et  al.  (9).  Those  amino  acids  of the  deduced 
sequence of l L-1-c~ cDNA, which have now been confirmed by direct amino acid 
sequence analysis of the purified protein, are in bold type in Fig.  10. 
Discussion 
We have described the  purification  to homogeneity of two anionic  forms of 
IL-1.  These  IL-1  species were more difficult to purify than  the pI  6.8  species 
because: (a)  they exist in  the  starting  supernatant  in  5-10-fold lesser amounts 
(this report and references 3 and 9), and (b) many of the contaminating proteins 
contained  in  the  starting  supernatant  display  behavior  similar  to  that  of the 
anionic  I L-1  species during  ion-exchange  chromatography.  Separation  of the 
anionic  IL-1  species from each other was accomplished by the use of a  shallow 
gradient of sodium acetate for elution from the DEAE/HPLC column (Fig.  1). 
The  use  of chloride  as  a  counter-ion  resulted  in  poor  separation  of the  two 
anionic species and a  much higher  level of contaminating  proteins.  Attempts to 
tnore selectively elute the anionic species of IL-1  by means of a descending pH 
gradient  (6.8-4.0),  such  as  the  approach  used  for  IL-1/6.8  (10),  were  also 
unsuccessful because only a  small  proportion  of the  bound activity eluted (un- 
published  observations).  Subsequent purification  of the  sodium  acetate  eluted 
peaks of activity by size exlusion, and reverse-phase chromatography (Figs. 2 and 
3) was sufficient to yield material that was homogeneous by SDS-PAGE (Fig. 4). 
The  estimated  recovery  of the  anionic  species,  though  low,  is  similar  to  that 
found for porcine catabolin  (18) and murine  IL-1  (19), two other anionic  IL-1 
molecules.  Most  of the  apparent  loss  of activity  occurred  during  the  anion- CAMERON  ET  AL.  247 
exchange HPLC step.  This  may be due,  at  least  in  part,  to  the  loss  of other 
potent thymocyte proliferation factors (e.g., IL-2) or the separation of unidenti- 
fied cofactors during this step.  Loss of bioactivity in partially purified prepara- 
tions during storage was a difficulty in preliminary studies, but this problem was 
overcome by the addition of aprotinin, PMSF, and EDTA to fractions obtained 
fi'om the ion-exchange and size-exclusion HPLC columns. These protease inhib- 
itors were readily resolved from IL-1  on reverse-phase HPLC, the final step in 
the purification protocol. 
The only previously reported purification of anionic human IL-1 (12) yielded 
a  protein (presumably a  mixture of IL-1/5.4  and IL-1/5.2) of 14,500  mol wt, 
which  was  -500-fold  less  active  on  a  mass basis  than  our pure  material.  No 
additional  biochemical characterization of this  material  was presented.  Other 
authors (20,  21) report the purification of human IL-1  without separating the 
neutral and anionic charged species from each other. Kronheim et al. (22) have 
purified a  17,500  mol  wt protein  having  IL-I  activity.  Analytical IEF  of this 
material yielded four silver-staining bands, suggesting that the various charged 
species of IL-I  had not been separated from each other. Therefore, the current 
report  is  the  first  in  which  the  two  native  anionic  IL-1  proteins  have  been 
separately isolated in pure form. 
The pure proteins are characterized as having mo| wts identical to IL-1/6.8 
(17,500,  Fig.  4) and pI  of 5.4  and  5.2  (Fig.  5).  These characteristics identify 
these  proteins  as  those  low  pI  IL-1  species  previously described  in  the  IL-1 
literature (2-6).  The specific activities of the purified anionic  IL-ls,  as deter- 
mined by half-maximal stimulation in the thymocyte comitogenic assay (Fig. 6), 
were identical to that of IL-1/6.8  (~1.2  x  l0 v u/mg [10,  13}) and in the same 
range as that reported for pure murine IL-1  (-2  x  107  U/mg [7]) and porcine 
catabolin (~5 x  106 U/mg [23]), two other anionic IL-1 molecules. It was found 
that  IL-1/5.4  and  IL-1/5.2  behaved  similarly,  though  not  identically,  when 
subjected to reverse-phase chromatography (Fig. 3). In contrast, the behavior of 
IL-1/6.8  on  reverse-phase differed significantly from the anionic species.  The 
striking  differences between the  peptide  maps  of IL-1/6.8  and  the  IL-1/5.4, 
their  substantially  different behavior  on  reverse-phase  HPLC,  as  well as  the 
inability of four different anti-IL-1/6.8 antisera to crossreact with IL-I/5.2 and 
IL-1/5.4,  clearly show  the significant structural  and antigenic differences be- 
tween these proteins. 
Recently the cloning of two human IL-1  cDNAs (a and/7) has been reported 
(8,  9).  That the /7 cDNA encodes the major species of human IL-1  having a pI 
of 6.8  has  been  conclusively shown  by  direct  comparison  of the  amino  acid 
sequence of the pure native protein  with  that  deduced from the nucleic acid 
sequence of the cDNA (9,  10,  13).  However, the relationsbip of the a  cDNA to 
the different charged species of IL-1  was not established.  We have sequenced 
the amino terminus of intact IL-1/5.2 and three CNBr peptides of IL-I/5.4 (Fig. 
9, A and B). Comparison of the amino acid sequences as obtained from the pure 
IL-1  species with  that  deduced from the IL-l-c~  cDNA clearly shows that  IL- 
l/5.2 and 1  L- 1/5.4 are encoded by the I L- 1-~ cDNA. 74 residues were identified. 
The amino terminal sequence of IL-I/5.2  (Fig.  9B) corresponds with residues 
119-158, while peptides I, II, and III of the IL-1/5.4 (Fig. 9A) correspond with 248  PURIFICATION  OF  TWO  ANIONIC  SPECIES  OF  INTERLEUKIN  1 
residues 169-186,208-226, and 128-166 deduced from the IL-l-a cDNA (Fig. 
10). Each of the peptides follows a  methionine, indicating that they are located 
internally within the sequence of the mature IL-1/5.4 molecule. It is also clear 
from these data that mature human IL-1/5.2 and IL-1/5.4 are derived from the 
C-terminal portion of the 31  kD precursor encoded by the IL-l-oe cDNA. Thus, 
as  in  the case  of IL-1/6.8,  most of the  processing of the precursor  molecule 
occurs at the amino terminal end. 
Our attempts to sequence the amino terminus of the mature IL-1/5.4 were 
unsuccessful, presumably due to the presence of an as yet unidentified blocking 
group.  Similar  difficulties were  encountered  with  murine  ILl  (7). However, 
after CNBr cleavage, the amino terminal peptide of murine IL-1 was susceptible 
to Edman degradation, and the apparent amino terminus was identified as Ser 
115.  The corresponding residue in the IL-l-o~-deduced sequence is Ser 113 (9). 
We were able to sequence the amino terminus of IL-1/5.2 and found Leu  119 
to be the amino terminal residue. Cleavage of the Phe-Leu linkage by a chymo- 
trypsin-like enzyme such  as  cathepsin  G  (24)  is  probably  responsible  for this 
terminus. Such cleavage may occur intracellularly, in the culture supernatant, or 
during the isolation procedure. In any event, the full activity of IL-1/5.2 in the 
thymocyte assay as  compared  with  IL-1/5.4,  IL-1/6.8,  and  murine  IL-1  (7) 
suggests that the amino acid residues that lie 5'  to Leu 119 are not essential to 
bioactivity. 
The amino acid sequences obtained have clarified the relationship between 
the two anionic species of human IL-1. As mentioned above, the amino terminus 
of  IL-1/5.4  is  apparently  blocked  while  the  amino  terminus  of IL-1/5.2  is 
susceptible  to  Edman  degradation.  Comparison of the  amino  acid  sequences 
determined for the two species shows that peptide III of IL-1/5.4 is homologous 
with the amino terminal sequence of IL-1/5.2, beginnning with Arg  128.  The 
homology is complete for all confirmed amino acid residues with one exception; 
residue 148 sequenced as Asn (underlined in Fig. 9A) in the case of peptide III, 
but as Asp (underlined in  Fig. 9B) in the amino terminal sequence.  This may 
account for the small difference in net charge between the two acidic species and 
may be  due  to either a  single base  change at the  nucleic acid  level or,  more 
likely, deamidation,  a  noncatalytic process  that  occurs  spontaneously during 
storage of proteins (25). 
Although the presence of additional IL-1  genes cannot be eliminated, it is now 
clear that the majority of the IL-1 activity, which resides in species having pI of 
6.8,  5.4,  and  5.2,  can  be  accounted  for  by  the  products  of two  genes.  The 
products of these genes, while indistinguishable from each other in the routine 
thymocyte assay,  are  structurally and  antigenically distinct  based  on  peptide 
analysis, primary amino acid sequence, and reactivity with antisera specific for 
IL-1/6.8. Now that these native IL-1  molecules are obtainable in pure form, it 
will be possible to determine their relative specific activities on other target cells. 
In addition, it shall also be possible to determine whether these different IL-1 
species  interact with a  single receptor  site  or different receptor sites  that use 
similar pathways of cellular activation. CAMERON  ET AL.  249 
Summary 
Two anionic species of human IL-1 have been purified to homogeneity. These 
molecules were characterized as having pI of 5.4 and 5.2 and molecular weights 
identical to IL-1/6.8 (17,500).  The specific activities of IL-1/5.4 and  IL-1/5.2, 
as measured in the mouse thymocyte comitogenic assay, were identical to that of 
IL-1/6.8, namely  1.2  ×  107  U/rag, with half-maximal stimulation observed at 2 
×  10 -l~  M.  IL-1/5.4 and IL-I/5.2 were found to be antigenically distinct from 
IL-1/6.8 in an ELISA. IL-1/5.4 was structurally distinct from IL-1/6.8 based on 
reverse-phase HPLC or CNBr peptides.  Intact IL-1/5.2 and three intact CNBr 
peptides of IL-1/5.4  were sequenced,  with  the  identification of 74 amino acid 
residues. These sequences were found to correspond exactly with the amino acid 
sequence deduced from the IL-l-a cDNA reported by March et al. (9). 
Received for publication  13 March 1986. 
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